- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 1.95 Å
- Oligo State
- hetero-1-1-mer
- Ligands
- 1 x K5A: 4-[(4-{[4-(4-cyano-2,6-dimethylphenoxy)thieno[3,2-d]pyrimidin-2-yl]amino}piperidin-1-yl)methyl]benzene-1-sulfonamide(Non-covalent)
- 1 x MG: MAGNESIUM ION(Non-covalent)
- 1 x NA: SODIUM ION(Non-functional Binders)
- 8 x SO4: SULFATE ION(Non-functional Binders)
SO4.4: 5 residues within 4Å:- Chain A: M.43, K.75, Y.148, P.152, Q.153
6 PLIP interactions:6 interactions with chain A- Hydrogen bonds: A:Y.148, A:Y.148, A:Q.153
- Water bridges: A:K.75, A:K.75
- Salt bridges: A:K.75
SO4.5: 4 residues within 4Å:- Chain A: K.333, G.335, Q.336, K.514
8 PLIP interactions:8 interactions with chain A- Hydrogen bonds: A:Q.336, A:Q.336
- Water bridges: A:K.333, A:D.366, A:K.514, A:K.514
- Salt bridges: A:K.333, A:K.514
SO4.6: 4 residues within 4Å:- Chain A: E.516, S.517, E.518, L.519
4 PLIP interactions:4 interactions with chain A- Hydrogen bonds: A:S.517, A:E.518, A:L.519
- Salt bridges: A:K.478
SO4.7: 5 residues within 4Å:- Chain A: K.103, K.105, V.181
- Chain B: K.138
- Ligands: K5A.1
6 PLIP interactions:2 interactions with chain B, 4 interactions with chain A- Water bridges: B:K.138, A:K.103, A:K.105
- Salt bridges: B:K.138, A:K.103, A:K.105
SO4.24: 4 residues within 4Å:- Chain A: Q.87
- Chain B: E.53, P.55, Y.56
2 PLIP interactions:2 interactions with chain B- Water bridges: B:E.53
- Salt bridges: B:K.126
SO4.25: 8 residues within 4Å:- Chain A: T.405, E.406, Y.407, W.408
- Chain B: K.331, Q.332, G.333, K.424
5 PLIP interactions:3 interactions with chain B, 2 interactions with chain A- Hydrogen bonds: B:K.331
- Water bridges: B:K.424, A:E.406, A:E.406
- Salt bridges: B:K.424
SO4.26: 4 residues within 4Å:- Chain B: I.274, K.275, V.276, R.277
3 PLIP interactions:2 interactions with chain B, 1 interactions with chain A- Hydrogen bonds: B:V.276, B:R.277
- Salt bridges: A:K.542
SO4.27: 4 residues within 4Å:- Chain B: L.234, H.235, W.239
- Ligands: EDO.32
3 PLIP interactions:3 interactions with chain B- Hydrogen bonds: B:H.235, B:H.235
- Water bridges: B:Y.232
- 26 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.8: 6 residues within 4Å:- Chain A: K.426, L.427, W.428, Y.429, Q.511, D.513
Ligand excluded by PLIPEDO.9: 7 residues within 4Å:- Chain A: L.488, S.491, G.492, L.493, Q.526, K.529, K.530
Ligand excluded by PLIPEDO.10: 4 residues within 4Å:- Chain A: W.90
- Chain B: K.20, V.21, K.22
Ligand excluded by PLIPEDO.11: 7 residues within 4Å:- Chain A: Q.163, I.182, Y.183, Q.184
- Chain B: K.138, T.139, P.140
Ligand excluded by PLIPEDO.12: 4 residues within 4Å:- Chain A: R.450, T.475, N.476, Q.477
Ligand excluded by PLIPEDO.13: 5 residues within 4Å:- Chain A: E.8, K.168
- Chain B: K.49, I.50, G.51
Ligand excluded by PLIPEDO.14: 2 residues within 4Å:- Chain A: W.268, Q.271
Ligand excluded by PLIPEDO.15: 3 residues within 4Å:- Chain A: E.398, E.401, T.402
Ligand excluded by PLIPEDO.16: 4 residues within 4Å:- Chain A: R.465, D.490, S.491, G.492
Ligand excluded by PLIPEDO.17: 3 residues within 4Å:- Chain A: Y.534, L.535, A.536
Ligand excluded by PLIPEDO.18: 2 residues within 4Å:- Chain A: Q.396, F.418
Ligand excluded by PLIPEDO.19: 6 residues within 4Å:- Chain A: Y.429, Q.430, L.527, K.530, E.531, V.533
Ligand excluded by PLIPEDO.20: 2 residues within 4Å:- Chain A: N.138, N.139
Ligand excluded by PLIPEDO.21: 4 residues within 4Å:- Chain A: K.103, D.322, P.323, S.324
Ligand excluded by PLIPEDO.22: 3 residues within 4Å:- Chain A: T.379, E.380, V.383
Ligand excluded by PLIPEDO.23: 4 residues within 4Å:- Chain A: N.56, Y.58, N.59, R.145
Ligand excluded by PLIPEDO.28: 4 residues within 4Å:- Chain B: W.24, E.399, W.402, T.403
Ligand excluded by PLIPEDO.29: 7 residues within 4Å:- Chain B: V.75, F.77, R.78, N.81, G.152, W.410, I.411
Ligand excluded by PLIPEDO.30: 6 residues within 4Å:- Chain A: W.90, V.92, S.164
- Chain B: I.50, G.51, P.52
Ligand excluded by PLIPEDO.31: 5 residues within 4Å:- Chain B: V.108, D.110, D.186, Y.232, Q.407
Ligand excluded by PLIPEDO.32: 6 residues within 4Å:- Chain B: Y.232, L.234, W.239, K.374, E.378
- Ligands: SO4.27
Ligand excluded by PLIPEDO.33: 5 residues within 4Å:- Chain A: I.382
- Chain B: T.27, T.400, W.401, E.404
Ligand excluded by PLIPEDO.34: 4 residues within 4Å:- Chain B: P.157, Q.182, Y.183, M.184
Ligand excluded by PLIPEDO.35: 5 residues within 4Å:- Chain A: Q.502, W.537
- Chain B: W.266, Q.269, W.426
Ligand excluded by PLIPEDO.36: 7 residues within 4Å:- Chain A: E.434, P.435
- Chain B: T.253, N.255, D.256, K.259, L.289
Ligand excluded by PLIPEDO.37: 4 residues within 4Å:- Chain B: K.66, Y.232, Q.373, A.408
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Yang, Y. et al., Structural basis for potent and broad inhibition of HIV-1 RT by thiophene[3,2-d]pyrimidine non-nucleoside inhibitors. Elife (2018)
- Release Date
- 2018-08-01
- Peptides
- Reverse transcriptase/ribonuclease H: A
Reverse transcriptase p51 subunit: B - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B
SMTL ID : 6c0l.1
Crystal structure of HIV-1 E138K mutant reverse transcriptase in complex with non-nucleoside inhibitor K-5a2
Reverse transcriptase/ribonuclease H
Reverse transcriptase p51 subunit
Related Entries With Identical Sequence
2zd1.1 | 4g1q.1 | 4h4m.1 | 4h4o.1 | 4i2p.1 | 4icl.1 | 4id5.1 | 4idk.1 | 4ifv.1 | 4ify.1 | 4ig0.1 | 4ig3.1 | 4kfb.1 | 4kko.1 | 4ko0.1 | 4lsl.1 | 4lsn.1 | 4mfb.1 | 4o44.1 | 4o4g.1 | 4rw8.1 | 4we1.1 | 5c25.1 | 5cym.1 | 5cyq.1 | 5hbm.1 | 5ter.1 | 5tw3.1 | 5vqq.1 | 5vqr.1 more...less...5vqs.1 | 5vqt.1 | 6c0j.1 | 6c0n.1 | 6c0p.1 | 6dtx.1 | 6oe3.1 | 6ul5.1 | 6x47.1 | 6x4b.1 | 6x4c.1 | 6x4d.1 | 6x4e.1 | 7krc.1 | 7krd.1 | 7kre.1 | 7krf.1 | 7kwu.1 | 7lpw.1 | 7lpx.1 | 7lqu.1 | 7snp.1 | 7snz.1 | 7so1.1 | 7taz.1 | 7u5z.1 | 7z29.1 | 7z2e.1 | 7z2h.1 | 8dx2.1 | 8dx3.1 | 8dx8.1 | 8dxb.1 | 8dxe.1 | 8dxg.1 | 8dxh.1 | 8dxi.1 | 8dxj.1 | 8dxk.1 | 8dxl.1 | 8dxm.1 | 8fe8.1 | 8ffx.1 | 8u69.1 | 8u6a.1 | 8u6b.1 | 8u6c.1 | 8u6d.1 | 8u6e.1 | 8u6j.1 | 8u6k.1 | 8u6l.1 | 8u6m.1 | 8u6p.1 | 8u6q.1 | 8vub.1